Let's focus on what we can do!

By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • EURETINA 2022 in review: A showcase of retinal revelations in Hamburg – Ophthalmology Times Europe

EURETINA 2022 in review: A showcase of retinal revelations in Hamburg – Ophthalmology Times Europe

Wednesday, 7 September, 2022

EURETINA 2022 in review: A showcase of retinal revelations in Hamburg – Ophthalmology Times Europe

A synopsis of the findings presented at EURETINA 2022 for ophthalmologists and retina specialists.

A gene therapy evaluated for diabetic retinopathy (DR), RGX-314 (REGENXBIO), may provide sustained clinical outcomes for treating DR. A major advantage is that this treatment can be administered once into the suprachoroidal space in an office setting, which markedly reduces the treatment burden, according to Dr Mark Barakat.

The Phase 2 Altitude study, an open-label, randomized, controlled, dose-escalation evaluation of RGX-314. It was conducted at 18 retina practices nationally and evaluated the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 using the SCS Microinjector (Clearside Biomedical) in patients with moderately severe/severe non-proliferative diabetic retinopathy (NPDR) or mild PDR.

Read more at: https://europe.ophthalmologytimes.com/view/euretina-2022-in-review-a-showcase-of-retinal-revelations-in-hamburg

Categories :
  • Latest Headlines
  • Visual Impairment
Socials :

Recent posts